Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review

Overview

Journal Chonnam Med J

Specialty General Medicine

Date 2023 Feb 16

PMID 36794237

Authors

Samaneh Keshavarz

Somayeh Keshavarz

Nasrin Ziamajidi

Sajedeh Daei

Affiliations

Soon will be listed here.

Abstract

The outbreak of the COVID-19 infection has led to the rapidity of vaccine usage in recent years. Emerging data indicate that the efficacy of vaccination against COVID-19 was about 95% in the general population, though its impact is impaired in patients with hematologic malignancies. As such, we decided to research the publications in which the authors reported the impacts of COVID-19 vaccination in patients suffering from hematologic malignancies. We concluded that patients with hematologic malignancies have lower responses, antibody titers as well as an impaired humoral response following vaccination, notably in patients with chronic lymphocytic leukemia (CLL) and lymphoma. Furthermore, it seems that the status of treatment can significantly affect the responses to the COVID-19 vaccination.

Citing Articles

Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.

Kontandreopoulou C, Solomou E, Kolorizos E, Diamantopoulos P Ann Hematol. 2024; 103(12):4971-4980.

PMID: 39008060 DOI: 10.1007/s00277-024-05869-8.

References

Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S . Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021; 11(7):136. PMC: 8323747. DOI: 10.1038/s41408-021-00528-x. View

Snow A, Zeidner J . The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?. Ther Adv Hematol. 2022; 13:20406207221112899. PMC: 9310330. DOI: 10.1177/20406207221112899. View

Pasikhova Y, Morrison A, Katzman J, Syed M . Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection. Cancer Control. 2022; 29:10732748211070720. PMC: 8744183. DOI: 10.1177/10732748211070720. View

Jurgens E, Ketas T, Zhao Z, Joseph Satlin M, Small C, Sukhu A . Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol. 2021; 96(11):E410-E413. PMC: 8420465. DOI: 10.1002/ajh.26322. View

Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O . Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2021; 139(5):678-685. PMC: 8648353. DOI: 10.1182/blood.2021014085. View

Agha M, Blake M, Chilleo C, Wells A, Haidar G . Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. Open Forum Infect Dis. 2021; 8(7):ofab353. PMC: 8320282. DOI: 10.1093/ofid/ofab353. View

Gurion R, Rozovski U, Itchaki G, Gafter-Gvili A, Leibovitch C, Raanani P . Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2021; 107(3):715-720. PMC: 8883526. DOI: 10.3324/haematol.2021.279216. View

Candoni A, Callegari C, Zannier M, Fanin R . Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax. Blood Adv. 2022; 6(10):3068-3071. PMC: 8813197. DOI: 10.1182/bloodadvances.2021006949. View

Monin L, Laing A, Munoz-Ruiz M, McKenzie D, Del Molino Del Barrio I, Alaguthurai T . Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021; 22(6):765-778. PMC: 8078907. DOI: 10.1016/S1470-2045(21)00213-8. View

10.

Crombie J, Sherman A, Cheng C, Ryan C, Zon R, Desjardins M . Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. Blood Adv. 2021; 5(16):3062-3065. PMC: 8362656. DOI: 10.1182/bloodadvances.2021005328. View

11.

Teh J, Coussement J, Neoh Z, Spelman T, Lazarakis S, Slavin M . Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2021; 6(7):2014-2034. PMC: 8639290. DOI: 10.1182/bloodadvances.2021006333. View

12.

Zhang D, Zheng Y, Lin Z, Liu X, Li J, Yang H . Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors. Angew Chem Int Ed Engl. 2020; 59(29):12022-12028. DOI: 10.1002/anie.202002145. View

13.

Mark C, Gupta S, Punnett A, Upton J, Orkin J, Atkinson A . Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer. 2021; 68(11):e29295. PMC: 8441639. DOI: 10.1002/pbc.29295. View

14.

Perry C, Luttwak E, Balaban R, Shefer G, Morales M, Aharon A . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021; 5(16):3053-3061. PMC: 8362658. DOI: 10.1182/bloodadvances.2021005094. View

15.

Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M . Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2021; 40(1):26-34. PMC: 8567287. DOI: 10.1080/07357907.2021.1992420. View

16.

Mori A, Onozawa M, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K . Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies. Br J Haematol. 2022; 197(6):691-696. PMC: 9111452. DOI: 10.1111/bjh.18138. View

17.

Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A . Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021; 195(2):186-193. PMC: 8444771. DOI: 10.1111/bjh.17608. View

18.

Pinana J, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez-Veiga R . Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leuk Lymphoma. 2021; 63(3):538-550. PMC: 8544670. DOI: 10.1080/10428194.2021.1992619. View

19.

Molica S, Giannarelli D, Lentini M, Zappala D, Mannella A, Loiacono D . Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study. Chemotherapy. 2021; 67(2):91-95. PMC: 8805055. DOI: 10.1159/000521229. View

20.

Foster C, Del Valle Penella A, Davis A, Arrington A, Campbell J, Palazzi D . Varicella-Zoster virus reactivation following SARS-CoV-2 immunization in two patients with leukemia. Pediatr Blood Cancer. 2021; 68(10):e29191. PMC: 8441675. DOI: 10.1002/pbc.29191. View